CRF receptor antagonists and methods relating thereto

Details CRF receptor antagonists and methods relating thereto CRF receptor antagonists and methods relating thereto

2005-12-13

2005-12-13

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S217030, C514S231500, C514S303000, C546S273400, C544S111000, C540S599000

Reexamination Certificate

active

06974808

ABSTRACT:
CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.

REFERENCES:
patent: 4605642 (1986-08-01), Rivier et al.
patent: 5063245 (1991-11-01), Abreu et al.
patent: 5464847 (1995-11-01), Courtemanche et al.
patent: 6352990 (2002-03-01), McCarthy
patent: 41399/93 (1994-01-01), None
patent: 0 773 023 (1997-05-01), None
patent: 0 778 277 (1997-05-01), None
patent: 0 812 831 (1997-12-01), None
patent: WO 94/13676 (1994-06-01), None
patent: WO 94/13677 (1994-06-01), None
patent: WO 95/33750 (1995-12-01), None
patent: WO 95/34563 (1995-12-01), None
patent: WO 96/35689 (1996-11-01), None
patent: WO 97/29109 (1997-08-01), None
patent: WO 98/03510 (1998-01-01), None
patent: WO 98/08846 (1998-03-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 98/35967 (1998-08-01), None
Mitchell, Neurosci. Neurosci. Biobehav. Rev. 22(5); 635-651, 1998.
Kiyama et al. Chem. Pharm. Bull., 43(3) 450-460, 1995.
Adamiak, et al.,Angew. Chem., 1985, 97/(12), 1046 (CA 104:110099, 1986).
Brown, et al.,J. Chem. Soc., 1969, C18, 2620-2624 (CA 72:21662, 1970).
Gundersen, et al.,Tetrahedron Letts., 1994, 50(32), 9743-9756.
Hamann, et al.,Can. J. Chem., 1968, 46(3), 419-423 (CA 68:68957, 1968).
J. Heterocycl. Chem., 1968, 5(5), 679-682 (CA 70:4052, 1969).
McKenzie, et al.,J. Org. Chem., 1982, 47(25), 4881-4884.
Stevenson, et al.,Tetrahedron Letts., 1996, 37(46), 8375-8378.
Wang, et al.,Biochem. Pharmacol., 1979, 28(15), 2249-2260 (CA 92:69336, 1980).
Al-Shaar. A..H., et al., “The synthesis of heterocycles via addition-elimination reactions of 4- and 5-aminoimidazoles,”J. Chem. Soc., Perkin Trans. 1, 1992, 2789-2793.
Balicki, R., et al., Translocative rearrangements. Generality of the formamidine-induced rearrangement of 4-substituted 5-amino-4-cyano-4H-imidazoles,J. Org. Chem., 1983, 48(1), 3-7.
Battaglia, G., et al., “Characterization of corticotrophin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system,”Synapse, Alan R. Liss, Inc. 1987, 1, 572-581.
Bilezikjian, L.M., et al., “Glucocorticoids inhibit Corticotrophin-releasing factor-induced production of adenosine 3′,5′-monophosphate in cultured anterior pituitary cells,”Endocrinology, 1983, 113(2), 657-662.
Boger, D.L., et al., “Inverse electron demand diels-alder reactions of heterocyclic aza dienes. Studies on the total synthesis of lavendamycin: investigative studies on the preparation of the CDE β-carboline ring system and AB quinoline-5,8-quinone ring system,”J. Org. Chem., 1985, 50(26), 5782-5789.
Borch, R.F., et al., “A new method for the methylation of amines,”J. Org. Chem., 1972, 37(10), 1673-1674.
Brown, M.R., et al., “Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism,”Endocrinology, 1982, 111(3), 928-931.
Brown, et al., “Corticotropin-releasing factor: effects on the sympatheic nervous system and oxygen consumption,”Life Sciences, 1982, 30, 207-210.
Chen, R., et al., “Expression cloning of a human corticotrophin-releasing-factor receptor,”PNAS, USA, Oct. 1993, 90, 8967-8971.
Cheng, Y.-C., et al., “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction,”Biochem. Pharmacol., 1973, 22, 3099-3108.
Chatani, N., et al., “Palladium- and nickel-catalyzed reaction of trimethylsilyl cyanide with acetylenes. Addition of trimethysilyl cyanide to the carbon-carbon triple bonds,”J. Org. Chem., 1988, 53, 3539-3548.
Corey, E.J., et al., “A synthetic method for formyl→ethynyl conversion (RCHO →RC≡CH or RC≡CR'),”Tetrahderon Letts., 1972, 36, 3769-3772.
Crofford, L.J., et al., “Local secretion of corticotrophin-releasing hormone in the joints of lewis rats with inflammatory arthritis,”J. Clin. Invest., Dec. 1992, 90, 2555-2564.
DeSouza, E.B., “Role of corticotrophin-releasing factor in neuropsychiatric disorders and neurodegenerative diseases,”Ann. Reports in Med. Chem., 1990, 25, Chapter 23, 215-223.
DeSouza, E.B., et al., “Corticotropin-releasing factor receptors in the pituitary gland and central nervous system: methods and overview,”Methods Enzymol., 1986, 124, 560-590.
DeSouza, E.B., et al., “Corticotropin-releasing factor receptors in rat forebrain autoradiographic identification,”Science, Jun. 1984, 224(4656, 1449-1451.
DeSouza, E.B., et al., “Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution,”J. of Neuroscience, Jan. 1987, 7(1), 88-100.
Ehlers, C.L., et al., “Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats,”Brain Res., 1983, 278, 332-336.
Estel, L., et al., “Metalation/SRN1 coupling in heterocyclic synthesis. A convenient methodology for ring functionalization,”J. Org. Chem., 1988, 53(12), 2740-2744.
Fisher, L.A., et al., “Corticotropin-releasing factor (CRF): Central effects on mean arerial pressure and heart rate in rats,”Endocrinology, 1982, 110(6), p. 2222.
Houston, D.M., et al., “Potential Inhibitors of S-adenosylmethionine-dependent methyltransferases. 8. Molecular dissections of carbocyclic 3-deazaadenosine as inhibitors of S-adenosylhomocysteine hydrolase,”J. Org. Chem., 1985, 28, 467-471.
Irwin, M., et al., “CRF activates autonomic nervous system and reduces natural killer cytotoxicity,”Am. J. Physiol., 1988, 255(5), R744-R747.
Klinge, D.E., et al., “Ring transformations in reactions of heterocyclic halogeno compounds with nucleophiles (XXXVI). Conversion of 4-amino-3-halogenopyridazines into pyrazoles and of 4-amino-3,6-dihalogenopyridazines into 1,2,4-triazoles,”J. of the Royal Netherlands Chem. Soc., Aug. 1974, 93(8), 236-239.
Kuraishi, T., et al., “The synthesis of imidazo [4,5-c]-, s-triazolo [4,3-b]-, and tetrazolo [1,5-b] pyridazines,”J. Heterocyclic Chem., Feb. 1964, 1(1), 42-47.
Levine, A.S., et al., “Effect of centrally administered corticotrophin releasing factor (CRF) on multiple feeding paradigms,”Neuropharmacology, 1983, 22(3A), 337-339.
Munson, P.J., et al., “LIGAND: A versatile computerized approach for characterization of ligand-binding systems,”Anal. Biochem., Academic Press, Inc. 1980, 107, 220-239.
Perrin, M.H., et al., “Corticotrophin-releasing factor binding to the anterior pituitary receptor is modulated by divalent cations and guanyl nucleotides,”Endocrinology, 1986, 118(3), 1171-1179.
Perrin, M.H., et al., “Cloning and functional expression of a rat brain corticotrophin releasing factor (CRF) receptor,”Endo., 1993, 133(6), 3058-3061.
Remington's Pharmaceutical Science, Gennaro (Ed.),Mack Publishing Co., Easton, PA, 1990.
Rivier, J., et al., “Characterization of rat hypothalmic corticotrophin-releasing factor,”Proc. Natl. Acad. Sci. USA, Aug. 1983, 80, 4851-4855.
Rivier, J., et al., “Synthetic competitive antagonists of corticotrophin-releasing factor: effect on ACTH secretion in the rat,”Science, May 1984, 224(4651), 889-891.
Sapolsky, R., et al., “Interleukin-1 stimulates the secretion of hypothalamic corticotrophin-releasing fatcor,”Science, Oct. 23, 1987, 238, 522-524.
Shibahara, S., et al., “Isolation and sequence analysis of the human corticotrophin-releasing factor precursor gene,”EMBO J., 1983, 2(5), 775-779.
Sirinathsinghji, D.J.S., et al., “Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat,”Nature, Sep. 15, 1983, 305, 232-235.
Sutton, R.E., et al., “Corticotrophin releasing factor produces behavioural activation in rats,&#

Affiliated with

Also associated with

Rating

CRF receptor antagonists and methods relating thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CRF receptor antagonists and methods relating thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CRF receptor antagonists and methods relating thereto will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3518052